Mentions in press and media 4
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jul 10, 2026 | Healome Therapeutics Raises £2 Million Seed Round To Advance Eye-Drop Matrix Technology For Ocular Surface Diseases | Healome Therapeutics, a University of Birmingham spinout developing a proprietary eye-drop matrix platform for ocular surface diseases, announced it has raised an oversubscribed £2 million seed funding round. The financing was led by Empiri... |
| Jul 7, 2026 | Healome Therapeutics Closes £2 Million Seed Round Led by Empirical Ventures to Advance Eye-Drop Matrix Technology for Ocular Surface Diseases | BIRMINGHAM, England, July 7, 2026 /PRNewswire/ -- Healome Therapeutics ("Healome"), a University of Birmingham spinout developing a proprietary eye-drop matrix technology for ocular surface diseases, has closed a GBP£2 million ove... |
| Jun 6, 2024 | Oshen supports Topadur in the development of a treatment for alopecia | Androgenic alopecia is the most common form of hair loss in both men and women. According to data published by the Journal of Clinical and Diagnostic Research, around 60% of the global population has hair thinning problems and pattern hair... |
Reviews 0
FAQ about Oshen
What has the press written about Oshen?
Parsers VC has collected 4 articles mentioning Oshen, among them “Healome Therapeutics Raises £2 Million Seed Round To Advance Eye-Drop Matrix Technology For Ocular Surface Diseases” (Jul 10, 2026) and “Healome Therapeutics Closes £2 Million Seed Round Led by Empirical Ventures to Advance Eye-Drop Matrix Technology for Ocular Surface Diseases” (Jul 7, 2026).
Is Oshen still active?
Oshen is probably closed: its latest activity on Parsers VC dates from Jul 11, 2026.